The role of leukotrienes in immunopathogenesis of rheumatoid arthritis

References

• Firestein GS. Evolving concepts of rheumatoid arthritis. Nature. 2003;423(6937): 356–361.
   PubMed Web of Science ®Google Scholar
• Noss EH, Brenner MB. The role and therapeutic implications of fibroblast-like synoviocytes in inflammation and cartilage erosion in rheumatoid arthritis. Immunol Rev. 2008;223: 252–270.
   PubMed Web of Science ®Google Scholar
• Serhan CN, Yacoubian S, Yang R. Anti-inflammatory and proresolving lipid mediators. Annu Rev Pathol. 2008;3: 279–312.
   PubMed Web of Science ®Google Scholar
• Shimizu T. Lipid mediators in health and disease: enzymes and receptors as therapeutic targets for the regulation of immunity and inflammation. Annu Rev Pharmacol Toxicol. 2009;49: 123–150.
   PubMed Web of Science ®Google Scholar
• Gursel T, Firat S, Ercan ZS. Increased serum leukotriene B4 level in the active stage of rheumatoid arthritis in children. Prostaglandins Leukot Essent Fatty Acids. 1997;56(3): 205–207.
   PubMedGoogle Scholar
• Grignani G, Zucchella M, Belai BN, Brocchieri A, Saporiti A, Cherie Ligniere EL. Levels of different metabolites of arachidonic acid in synovial fluid of patients with arthrosis or rheumatoid arthritis. Minerva Med. 1996;87(3): 75–79.
   PubMedGoogle Scholar
• Bailie MB, Standiford TJ, Laichalk LL, Coffey MJ, Strieter R, Peters-Golden M. Leukotriene-deficient mice manifest enhanced lethality from Klebsiella pneumonia in association with decreased alveolar macrophage phagocytic and bactericidal activities. J Immunol. 1996;157(12): 5221–5224.
   PubMedGoogle Scholar
• Benjamim CF, Canetti C, Cunha FQ, Kunkel SL, Peters-Golden M. Opposing and hierarchical roles of leukotrienes in local innate immune versus vascular responses in a model of sepsis. J Immunol. 2005;174(3): 1616–1620.
   PubMedGoogle Scholar
• Samuelsson B, Dahlen SE, Lindgren JA, Rouzer CA, Serhan CN. Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science. 1987;237(4819): 1171–1176.
   PubMedGoogle Scholar
• Michel AA, Steinhilber D, Werz O. Development of a method for expression and purification of the regulatory C2-like domain of human 5-lipoxygenase. Protein Expr Purif. 2008;59(1): 110–116.
   PubMedGoogle Scholar
• Maas RL, Ingram CD, Taber DF, Oates JA, Brash AR. Stereospecific removal of the DR hydrogen atom at the 10-carbon of arachidonic acid in the biosynthesis of leukotriene A4 by human leukocytes. J Biol Chem. 1982;257(22): 13515–13519.
   PubMedGoogle Scholar
• Shimizu T, Radmark O, Samuelsson B. Enzyme with dual lipoxygenase activities catalyzes leukotriene A4 synthesis from arachidonic acid. Proc Natl Acad Sci USA. 1984;81(3): 689–693.
   PubMedGoogle Scholar
• Abramovitz M, Wong E, Cox ME, Richardson CD, Li C, Vickers PJ. 5-Lipoxygenase-activating protein stimulates the utilization of arachidonic acid by 5-lipoxygenase. Eur J Biochem. 1993;215(1): 105–111.
   PubMedGoogle Scholar
• Neu I, Mallinger J, Wildfeuer A, Mehlber L. Leukotrienes in the cerebrospinal fluid of multiple sclerosis patients. Acta Neurol Scand. 1992;86(6): 586–587.
   PubMedGoogle Scholar
• Brock TG, Paine RIII, Peters-Golden M. Localization of 5-lipoxygenase to the nucleus of unstimulated rat basophilic leukemia cells. J Biol Chem. 1994;269(35): 22059–22066.
   PubMedGoogle Scholar
• Woods JW, Evans JF, Ethier D, Scott S, Vickers PJ, Hearn L, et al. 5-Lipoxygenase and 5-lipoxygenase-activating protein are localized in the nuclear envelope of activated human leukocytes. J Exp Med. 1993;178(6): 1935–1946.
   PubMedGoogle Scholar
• Clark SR, Coffey MJ, Maclean RM, Collins PW, Lewis MJ, Cross AR, et al. Characterization of nitric oxide consumption pathways by normal, chronic granulomatous disease and myeloperoxidase-deficient human neutrophils. J Immunol. 2002;169(10): 5889–5896.
   PubMedGoogle Scholar
• Rouzer CA, Matsumoto T, Samuelsson B. Single protein from human leukocytes possesses 5-lipoxygenase and leukotriene A4 synthase activities. Proc Natl Acad Sci USA. 1986;83(4): 857–861.
   PubMed Web of Science ®Google Scholar
• Lewis RA, Austen KF, Soberman RJ. Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. N Engl J Med. 1990;323(10): 645–655.
   PubMedGoogle Scholar
• Penrose JF. LTC4 synthase. Enzymology, biochemistry, and molecular characterization. Clin Rev Allergy Immunol. 1999;17(1–2): 133–152.
   PubMedGoogle Scholar
• Bernstrom K, Orning L, Hammarstrom S. Gamma-glutamyl transpeptidase, a leukotriene metabolizing enzyme. Methods Enzymol. 1982;86: 38–45.
   PubMedGoogle Scholar
• Nagaoka I, Yamada M, Kira S, Yamashita T. Comparative studies on the leukotriene D4-metabolizing enzyme of different types of leukocytes. Comp Biochem Physiol B. 1988;89(2): 375–380.
   PubMedGoogle Scholar
• Raulf M, Konig W, Koller M, Stuning M. Release and functional characterization of the leukotriene D4-metabolizing enzyme (dipeptidase) from human polymorphonuclear leucocytes. Scand J Immunol. 1987;25(3): 305–313.
   PubMedGoogle Scholar
• Haeggstrom JZ, Kull F, Rudberg PC, Tholander F, Thunnissen MM. Leukotriene A4 hydrolase. Prostaglandins Other Lipid Mediat. 2002;68–69: 495–510.
   PubMedGoogle Scholar
• Maclouf J, Antoine C, Henson PM, Murphy RC. Leukotriene C4 formation by transcellular biosynthesis. Ann N Y Acad Sci. 1994;714: 143–150.
   PubMedGoogle Scholar
• Maclouf J, Sala A, Rossoni G, Berti F, Muller-Peddinghaus R, Folco G. Consequences of transcellular biosynthesis of leukotriene C4 on organ function. Haemostasis. 1996;26(Suppl 4): 28–36.
   PubMedGoogle Scholar
• Ciana P, Fumagalli M, Trincavelli ML, Verderio C, Rosa P, Lecca D, et al. The orphan receptor GPR17 identified as a new dual uracil nucleotides/cysteinyl-leukotrienes receptor. EMBO J. 2006;25(19): 4615–4627.
   PubMedGoogle Scholar
• Lynch KR, O’Neill GP, Liu Q, Im DS, Sawyer N, Metters KM, et al. Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature. 1999;399(6738): 789–793.
   PubMedGoogle Scholar
• Mellor EA, Maekawa A, Austen KF, Boyce JA. Cysteinyl leukotriene receptor 1 is also a pyrimidinergic receptor and is expressed by human mast cells. Proc Natl Acad Sci USA. 2001;98(14): 7964–7969.
   PubMedGoogle Scholar
• Sarau HM, Ames RS, Chambers J, Ellis C, Elshourbagy N, Foley JJ, et al. Identification, molecular cloning, expression, and characterization of a cysteinyl leukotriene receptor. Mol Pharmacol. 1999;56(3): 657–663.
   PubMedGoogle Scholar
• Nielsen CK, Campbell JI, Ohd JF, Morgelin M, Riesbeck K, Landberg G, et al. A novel localization of the G-protein-coupled CysLT1 receptor in the nucleus of colorectal adenocarcinoma cells. Cancer Res. 2005;65(3): 732–742.
   PubMedGoogle Scholar
• Heise CE, O’Dowd BF, Figueroa DJ, Sawyer N, Nguyen T, Im DS, et al. Characterization of the human cysteinyl leukotriene 2 receptor. J Biol Chem. 2000;275(39): 30531–30536.
   PubMedGoogle Scholar
• Sjostrom M, Johansson AS, Schroder O, Qiu H, Palmblad J, Haeggstrom JZ. Dominant expression of the CysLT2 receptor accounts for calcium signaling by cysteinyl leukotrienes in human umbilical vein endothelial cells. Arterioscler Thromb Vasc Biol. 2003;23(8): e37–e41.
   PubMedGoogle Scholar
• Lecca D, Trincavelli ML, Gelosa P, Sironi L, Ciana P, Fumagalli M, et al. The recently identified P2Y-like receptor GPR17 is a sensor of brain damage and a new target for brain repair. PLoS One. 2008;3(10): e3579.
   PubMedGoogle Scholar
• Communi D, Janssens R, Suarez-Huerta N, Robaye B, Boeynaems JM. Advances in signalling by extracellular nucleotides. The role and transduction mechanisms of P2Y receptors. Cell Signal. 2000;12(6): 351–360.
   PubMedGoogle Scholar
• Stucky CL, Medler KA, Molliver DC. The P2Y agonist UTP activates cutaneous afferent fibers. Pain. 2004;109(1–2): 36–44.
   PubMedGoogle Scholar
• Haynes SE, Hollopeter G, Yang G, Kurpius D, Dailey ME, Gan WB, et al. The P2Y12 receptor regulates microglial activation by extracellular nucleotides. Nat Neurosci. 2006;9(12): 1512–1519.
   PubMedGoogle Scholar
• Koizumi S, Shigemoto-Mogami Y, Nasu-Tada K, Shinozaki Y, Ohsawa K, Tsuda M, et al. UDP acting at P2Y6 receptors is a mediator of microglial phagocytosis. Nature. 2007;446(7139): 1091–1095.
   PubMedGoogle Scholar
• Back M, Bu DX, Branstrom R, Sheikine Y, Yan ZQ, Hansson GK. Leukotriene B4 signaling through NF-kappaB-dependent BLT1 receptors on vascular smooth muscle cells in atherosclerosis and intimal hyperplasia. Proc Natl Acad Sci USA. 2005;102(48): 17501–17506.
   PubMedGoogle Scholar
• Qiu H, Johansson AS, Sjostrom M, Wan M, Schroder O, Palmblad J, et al. Differential induction of BLT receptor expression on human endothelial cells by lipopolysaccharide, cytokines, and leukotriene B4. Proc Natl Acad Sci USA. 2006;103(18): 6913–6918.
   PubMedGoogle Scholar
• Toda A, Yokomizo T, Shimizu T. Leukotriene B4 receptors. Prostaglandins Other Lipid Mediat. 2002;68–69: 575–585.
   PubMed Web of Science ®Google Scholar
• Devchand PR, Keller H, Peters JM, Vazquez M, Gonzalez FJ, Wahli W. The PPARalpha-leukotriene B4 pathway to inflammation control. Nature. 1996;384(6604): 39–43.
   PubMedGoogle Scholar
• Peres CM, Aronoff DM, Serezani CH, Flamand N, Faccioli LH, Peters-Golden M. Specific leukotriene receptors couple to distinct G proteins to effect stimulation of alveolar macrophage host defense functions. J Immunol. 2007;179(8): 5454–5461.
   PubMedGoogle Scholar
• Jiang Y, Borrelli LA, Kanaoka Y, Bacskai BJ, Boyce JA. CysLT2 receptors interact with CysLT1 receptors and down-modulate cysteinyl leukotriene dependent mitogenic responses of mast cells. Blood. 2007;110(9): 3263–3270.
   PubMedGoogle Scholar
• Yokomizo T, Kato K, Terawaki K, Izumi T, Shimizu T. A second leukotriene B(4) receptor, BLT2. A new therapeutic target in inflammation and immunological disorders. J Exp Med. 2000;192(3): 421–432.
   PubMedGoogle Scholar
• Gagnon L, Girard M, Sullivan AK, Rola-Pleszczynski M. Augmentation of human natural cytotoxic cell activity by leukotriene B4 mediated by enhanced effector-target cell binding and increased lytic efficiency. Cell Immunol. 1987;110(2): 243–252.
   PubMedGoogle Scholar
• Rola-Pleszczynski M, Gagnon L, Sirois P. Leukotriene B4 augments human natural cytotoxic cell activity. Biochem Biophys Res Commun. 1983;113(2): 531–537.
   PubMedGoogle Scholar
• Yamaoka KA, Claesson HE, Rosen A. Leukotriene B4 enhances activation, proliferation, and differentiation of human B lymphocytes. J Immunol. 1989;143(6): 1996–2000.
   PubMedGoogle Scholar
• Wang S, Gustafson E, Pang L, Qiao X, Behan J, Maguire M, et al. A novel hepatointestinal leukotriene B4 receptor. Cloning and functional characterization. J Biol Chem. 2000;275(52): 40686–40694.
   PubMedGoogle Scholar
• Haneda Y, Hasegawa S, Hirano R, Hashimoto K, Ohsaki A, Ichiyama T. Leukotriene D(4) enhances tumor necrosis factor-alpha-induced vascular endothelial growth factor production in human monocytes/macrophages. Cytokine. 2011. [Epub ahead of print].
   PubMedGoogle Scholar
• Sala A, Zarini S, Bolla M. Leukotrienes: lipid bioeffectors of inflammatory reactions. Biochemistry (Mosc). 1998;63(1): 84–92.
   PubMedGoogle Scholar
• Sharma JN, Mohammed LA. The role of leukotrienes in the pathophysiology of inflammatory disorders: is there a case for revisiting leukotrienes as therapeutic targets? Inflammopharmacology. 2006;14(1–2):10–6.
   PubMedGoogle Scholar
• Yokomizo T, Izumi T, Shimizu T. Co-expression of two LTB4 receptors in human mononuclear cells. Life Sci. 2001;68(19–20): 2207–2212.
   PubMedGoogle Scholar
• Kato K, Yokomizo T, Izumi T, Shimizu T. Cell-specific transcriptional regulation of human leukotriene B(4) receptor gene. J Exp Med. 2000;192(3): 413–420.
   PubMedGoogle Scholar
• Yokomizo T, Izumi T, Chang K, Takuwa Y, Shimizu T. A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis. Nature. 1997;387(6633): 620–624.
   PubMedGoogle Scholar
• Kamohara M, Takasaki J, Matsumoto M, Saito T, Ohishi T, Ishii H, et al. Molecular cloning and characterization of another leukotriene B4 receptor. J Biol Chem. 2000;275(35): 27000–27004.
   PubMedGoogle Scholar
• Tryselius Y, Nilsson NE, Kotarsky K, Olde B, Owman C. Cloning and characterization of cDNA encoding a novel human leukotriene B(4) receptor. Biochem Biophys Res Commun. 2000;274(2): 377–382.
   PubMedGoogle Scholar
• Mathis SP, Jala VR, Lee DM, Haribabu B. Nonredundant roles for leukotriene B4 receptors BLT1 and BLT2 in inflammatory arthritis. J Immunol. 2010;185(5): 3049–3056.
   PubMedGoogle Scholar
• Hashimoto A, Endo H, Hayashi I, Murakami Y, Kitasato H, Kono S, et al. Differential expression of leukotriene B4 receptor subtypes (BLT1 and BLT2) in human synovial tissues and synovial fluid leukocytes of patients with rheumatoid arthritis. J Rheumatol. 2003;30(8): 1712–1718.
   PubMedGoogle Scholar
• Nicolete R, Rius C, Piqueras L, Jose PJ, Sorgi CA, Soares EG, et al. Leukotriene B4-loaded microspheres: a new therapeutic strategy to modulate cell activation. BMC Immunol. 2008;9: 36.
   PubMedGoogle Scholar
• Leibbrandt A, Penninger JM. RANK(L) as a key target for controlling bone loss. Adv Exp Med Biol. 2009;647: 130–145.
   PubMedGoogle Scholar
• Chen ZK, Lv HS, Jiang J. LTB4 can stimulate human osteoclast differentiation dependent of RANKL. Artif Cells Blood Substit Immobil Biotechnol. 2010;38(1): 52–56.
   PubMedGoogle Scholar
• Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999;401(6754): 708–712.
   PubMed Web of Science ®Google Scholar
• Ott VL, Cambier JC, Kappler J, Marrack P, Swanson BJ. Mast cell-dependent migration of effector CD8+ T cells through production of leukotriene B4. Nat Immunol. 2003;4(10): 974–981.
   PubMedGoogle Scholar
• Goodarzi K, Goodarzi M, Tager AM, Luster AD, Andrian UH. Leukotriene B4 and BLT1 control cytotoxic effector T cell recruitment to inflamed tissues. Nat Immunol. 2003;4(10): 965–973.
   PubMedGoogle Scholar
• Miyahara N, Takeda K, Miyahara S, Matsubara S, Koya T, Joetham A, et al. Requirement for leukotriene B4 receptor 1 in allergen-induced airway hyperresponsiveness. Am J Respir Crit Care Med. 2005;172(2): 161–167.
   PubMedGoogle Scholar
• Mathis S, Jala VR, Haribabu B. Role of leukotriene B4 receptors in rheumatoid arthritis. Autoimmun Rev. 2007;7(1): 12–17.
   PubMedGoogle Scholar
• Lee DM, Friend DS, Gurish MF, Benoist C, Mathis D, Brenner MB. Mast cells: a cellular link between autoantibodies and inflammatory arthritis. Science. 2002;297(5587): 1689–1692.
   PubMedGoogle Scholar
• Griffiths RJ, Smith MA, Roach ML, Stock JL, Stam EJ, Milici AJ, et al. Collagen-induced arthritis is reduced in 5-lipoxygenase-activating protein-deficient mice. J Exp Med. 1997;185(6): 1123–1129.
   PubMedGoogle Scholar
• Canetti CA, Leung BP, Culshaw S, McInnes IB, Cunha FQ, Liew FY. IL-18 enhances collagen-induced arthritis by recruiting neutrophils via TNF-alpha and leukotriene B4. J Immunol. 2003;171(2): 1009–1015.
   PubMedGoogle Scholar
• McInnes IB. Leukotrienes, mast cells, and T cells. Arthritis Res Ther. 2003;5(6): 288–289.
   PubMedGoogle Scholar
• Gaffo A, Saag KG, Curtis JR. Treatment of rheumatoid arthritis. Am J Health Syst Pharm. 2006;63(24): 2451–2465.
   PubMedGoogle Scholar
• Feldmann M, Maini RN. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?. Annu Rev Immunol. 2001;19: 163–196.
   PubMed Web of Science ®Google Scholar
• Henderson WRJr. The role of leukotrienes in inflammation. Ann Intern Med. 1994;121(9): 684–697.
   PubMedGoogle Scholar
• Massoumi R, Sjolander A. The role of leukotriene receptor signaling in inflammation and cancer. ScientificWorldJournal. 2007;7: 1413–1421.
   PubMed Web of Science ®Google Scholar
• Hikiji H, Takato T, Shimizu T, Ishii S. The roles of prostanoids, leukotrienes, and platelet-activating factor in bone metabolism and disease. Prog Lipid Res. 2008;47(2): 107–126.
   PubMedGoogle Scholar
• Ahmadzadeh N, Shingu M, Nobunaga M, Tawara T. Relationship between leukotriene B4 and immunological parameters in rheumatoid synovial fluids. Inflammation. 1991;15(6): 497–503.
   PubMed Web of Science ®Google Scholar
• Cuzzocrea S, Rossi A, Mazzon E, Di PR, Genovese T, Muia C, et al. 5-Lipoxygenase modulates colitis through the regulation of adhesion molecule expression and neutrophil migration. Lab Invest. 2005;85(6): 808–822.
   PubMedGoogle Scholar
• Cuzzocrea S, Rossi A, Serraino I, Mazzon E, Di PR, Dugo L, et al. 5-Lipoxygenase knockout mice exhibit a resistance to pleurisy and lung injury caused by carrageenan. J Leukoc Biol. 2003;73(6): 739–746.
   PubMedGoogle Scholar
• Krönke G, Katzenbeisser J, Uderhardt S, Zaiss MM, Scholtysek C, et al. 12/15-Lipoxygenase counteracts inflammation and tissue damage in arthritis. J Immunol. 2009;183(5): 3383–3389.
   PubMedGoogle Scholar
• Serhan CN, Chiang N, Dyke TE. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol. 2008;8(5): 349–361.
   PubMedGoogle Scholar
• Serhan CN, Jain A, Marleau S, Clish C, Kantarci A, et al. Reduced inflammation and tissue damage in transgenic rabbits overexpressing 15-lipoxygenase and endogenous anti-inflammatory lipid mediators. J Immunol. 2003;171(12): 6856–6865.
   PubMedGoogle Scholar
• Wen Y, Gu J, Chakrabarti SK, Aylor K, Marshall J, et al. The role of 12/15-lipoxygenase in the expression of interleukin-6 and tumor necrosis factor-alpha in macrophages. Endocrinology. 2007;148(3): 1313–1322.
   PubMedGoogle Scholar
• Wick G, Knoflach M, Xu Q. Autoimmune and inflammatory mechanisms in atherosclerosis. Annu Rev Immunol. 2004;22: 361–403.
   PubMed Web of Science ®Google Scholar
• Flamand L, Tremblay MJ, Borgeat P. Leukotriene B4 triggers the in vitro and in vivo release of potent antimicrobial agents. J Immunol. 2007;178(12): 8036–8045.
   PubMedGoogle Scholar
• Chen M, Lam BK, Kanaoka Y, Nigrovic PA, Audoly LP, Austen KF, et al. Neutrophil-derived leukotriene B4 is required for inflammatory arthritis. J Exp Med. 2006;203(4): 837–842.
   PubMedGoogle Scholar
• Hallett MB, Williams AS. Stopping the traffic: a route to arthritis therapy. Eur J Immunol. 2008;38(10): 2650–2653.
   PubMedGoogle Scholar
• Diaz-Gonzalez F, Alten RH, Bensen WG, Brown JP, Sibley JT, Dougados M, et al. Clinical trial of a leucotriene B4 receptor antagonist, BIIL 284, in patients with rheumatoid arthritis. Ann Rheum Dis. 2007;66(5):628–32.
   PubMedGoogle Scholar
• Nigrovic PA, Lee DM. Mast cells in inflammatory arthritis. Arthritis Res Ther. 2005;7(1): 1–11.
   PubMedGoogle Scholar
• Eklund KK. Mast cells in the pathogenesis of rheumatic diseases and as potential targets for anti-rheumatic therapy. Immunol Rev. 2007;217: 38–52.
   PubMed Web of Science ®Google Scholar
• Maruotti N, Crivellato E, Cantatore FP, Vacca A, Ribatti D. Mast cells in rheumatoid arthritis. Clin Rheumatol. 2007;26(1): 1–4.
   PubMedGoogle Scholar
• McLachlan JB, Hart JP, Pizzo SV, Shelburne CP, Staats HF, Gunn MD, et al. Mast cell-derived tumor necrosis factor induces hypertrophy of draining lymph nodes during infection. Nat Immunol. 2003;4(12): 1199–1205.
   PubMedGoogle Scholar
• Woolley DE, Tetlow LC. Mast cell activation and its relation to proinflammatory cytokine production in the rheumatoid lesion. Arthritis Res. 2000;2(1): 65–74.
   PubMedGoogle Scholar
• Harris RR, Carter GW, Bell RL, Moore JL, Brooks DW. Clinical activity of leukotriene inhibitors. Int J Immunopharmacol. 1995;17(2): 147–156.
   PubMedGoogle Scholar
• Xu S, Lu H, Lin J, Chen Z, Jiang D. Regulation of TNFalpha and IL1beta in rheumatoid arthritis synovial fibroblasts by leukotriene B4. Rheumatol Int. 2010;30(9): 1183–1189.
   PubMedGoogle Scholar
• Lindner SC, Kohl U, Maier TJ, Steinhilber D, Sorg BL. TLR2 ligands augment cPLA2alpha activity and lead to enhanced leukotriene release in human monocytes. J Leukoc Biol. 2009;86(2): 389–399.
   PubMedGoogle Scholar
• Lefebvre JS, Levesque T, Picard S, Pare G, Gravel A, Flamand L, et al. The extra domain A of fibronectin primes leukotriene biosynthesis and stimulates neutrophil migration through toll-like receptor 4 activation. Arthritis Rheum. 2011;63(6):1527–33.
   PubMedGoogle Scholar
• Simmonds RE, Foxwell BM. Signalling, inflammation and arthritis: NF-kappaB and its relevance to arthritis and inflammation. Rheumatology (Oxford). 2008;47(5): 584–590.
   PubMedGoogle Scholar
• Mankan AK, Lawless MW, Gray SG, Kelleher D, McManus R. NF-kappaB regulation: the nuclear response. J Cell Mol Med. 2009;13(4): 631–643.
   PubMedGoogle Scholar
• Sanchez-Galan E, Gomez-Hernandez A, Vidal C, Martin-Ventura JL, Blanco-Colio LM, Munoz-Garcia B, et al. Leukotriene B4 enhances the activity of nuclear factor-kappaB pathway through BLT1 and BLT2 receptors in atherosclerosis. Cardiovasc Res. 2009;81(1): 216–225.
   PubMedGoogle Scholar
• Serezani CH, Lewis C, Jancar S, Peters-Golden M. Leukotriene B4 amplifies NF-kappaB activation in mouse macrophages by reducing SOCS1 inhibition of MyD88 expression. J Clin Invest. 2011;121(2): 671–682.
   PubMedGoogle Scholar
• Abramson S, Edelson H, Kaplan H, Given W, Weissmann G. The neutrophil in rheumatoid arthritis: its role and the inhibition of its activation by nonsteroidal antiinflammatory drugs. Semin Arthritis Rheum. 1983;13(1 Suppl 1): 148–153.
   PubMedGoogle Scholar
• Buch MH, Emery P. New therapies in the management of rheumatoid arthritis. Curr Opin Rheumatol. 2011;23(3): 245–251.
   PubMedGoogle Scholar
• Passalacqua G, Ciprandi G, Scordamaglia A, Canonica GW. Anti-leukotriene agents: rationale for and prospects of use. Ann Ital Med Int. 1996;11(Suppl 2): 93S–96S.
   PubMedGoogle Scholar
• Anderson GD, Keys KL, Ciechi PA, Masferrer JL. Combination therapies that inhibit cyclooxygenase-2 and leukotriene synthesis prevent disease in murine collagen induced arthritis. Inflamm Res. 2009;58(2): 109–117.
   PubMedGoogle Scholar
• Rainsford KD, Ying C, Smith F. Effects of 5-lipoxygenase inhibitors on interleukin production by human synovial tissues in organ culture: comparison with interleukin-1-synthesis inhibitors. J Pharm Pharmacol. 1996;48(1): 46–52.
   PubMedGoogle Scholar
• Schiff M. Emerging treatments for rheumatoid arthritis. Am J Med. 1997;102(1A):11S–5S.
   PubMedGoogle Scholar
• Ammon HP. Boswellic acids (components of frankincense) as the active principle in treatment of chronic inflammatory diseases. Wien Med Wochenschr. 2002;152(15–16): 373–378.
   PubMedGoogle Scholar
• Poeckel D, Werz O. Boswellic acids: biological actions and molecular targets. Curr Med Chem. 2006;13(28): 3359–3369.
   PubMedGoogle Scholar
• Cuaz-Perolin C, Billiet L, Bauge E, Copin C, Scott-Algara D, Genze F, et al. Antiinflammatory and antiatherogenic effects of the NF-kappaB inhibitor acetyl-11-keto-beta-boswellic acid in LPS-challenged ApoE−/− mice. Arterioscler Thromb Vasc Biol. 2008;28(2): 272–277.
   PubMedGoogle Scholar
• Takada Y, Ichikawa H, Badmaev V, Aggarwal BB. Acetyl-11-keto-beta-boswellic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing NF-kappa B and NF-kappa B-regulated gene expression. J Immunol. 2006;176(5): 3127–3140.
   PubMedGoogle Scholar
• Tsuji F, Miyake Y, Horiuchi M, Mita S. Involvement of leukotriene B4 in murine dermatitis models. Biochem Pharmacol. 1998;55(3): 297–304.
   PubMedGoogle Scholar
• Rask-Madsen J, Bukhave K, Laursen LS, Lauritsen K. 5-Lipoxygenase inhibitors in the treatment of inflammatory bowel disease. Adv Prostaglandin Thromboxane Leukot Res. 1994;22: 113–124.
   PubMedGoogle Scholar
• Datta K, Biswal SS, Kehrer JP. The 5-lipoxygenase-activating protein (FLAP) inhibitor, MK886, induces apoptosis independently of FLAP. Biochem J. 1999;340(Pt 2): 371–375.
   PubMedGoogle Scholar
• Fretland DJ, Anglin CP, Bremer M, Isakson P, Widomski DL, Paulson SK, et al. Antiinflammatory effects of second-generation leukotriene B4 receptor antagonist, SC-53228: impact upon leukotriene B4- and 12(R)-HETE-mediated events. Inflammation. 1995;19(2): 193–205.
   PubMedGoogle Scholar
• Griffiths RJ, Pettipher ER, Koch K, Farrell CA, Breslow R, Conklyn MJ, et al. Leukotriene B4 plays a critical role in the progression of collagen-induced arthritis. Proc Natl Acad Sci USA. 1995;92(2): 517–521.
   PubMedGoogle Scholar
• Dunn CJ, Goa KL. Zafirlukast: an update of its pharmacology and therapeutic efficacy in asthma. Drugs. 2001;61(2): 285–315.
   PubMedGoogle Scholar
• Bonnet C, Bertin P, Cook-Moreau J, Chable-Rabinovitch H, Treves R, Rigaud M. Lipoxygenase products and expression of 5-lipoxygenase and 5-lipoxygenase-activating protein in human cultured synovial cells. Prostaglandins. 1995;50(3): 127–135.
   PubMedGoogle Scholar
• Rola-Pleszczynski M, Bouvrette L, Gingras D, Girard M. Identification of interferon-gamma as the lymphokine that mediates leukotriene B4-induced immunoregulation. J Immunol. 1987;139(2): 513–517.
   PubMedGoogle Scholar
• Leppert D, Hauser SL, Kishiyama JL, An S, Zeng L, Goetzl EJ. Stimulation of matrix metalloproteinase-dependent migration of T cells by eicosanoids. FASEB J. 1995;9(14): 1473–1481.
   PubMedGoogle Scholar
• Grespan R, Fukada SY, Lemos HP, Vieira SM, Napimoga MH, Teixeira MM, et al. CXCR2-specific chemokines mediate leukotriene B4-dependent recruitment of neutrophils to inflamed joints in mice with antigen-induced arthritis. Arthritis Rheum. 2008;58(7): 2030–2040.
   PubMedGoogle Scholar